Corbus Pharmaceuticals Announces First Patient Dosed in Phase 2 Study of Resunab for Systemic Sclerosis October 7, 2015
Corbus Pharmaceuticals to Present Additional Data on the Effects of Resunab(TM) in the Treatment of Pulmonary Infection and Inflammation in Pre-Clinical Models of Cystic Fibrosis September 22, 2015
Corbus Pharmaceuticals Commences Patient Enrollment in Phase 2 Clinical Study of Resunab(TM) for the Treatment of Cystic Fibrosis September 21, 2015
Corbus Pharmaceuticals Commences Patient Enrollment in Phase 2 Clinical Study of Resunab(TM) for the Treatment of Systemic Sclerosis August 31, 2015
Corbus Pharmaceuticals Successfully Completes Warrant Call -- Raises $11.3 mm in Total From 100% Exercise of Callable Warrants August 27, 2015
Corbus Pharmaceuticals' Investigational Drug Resunab(TM) Granted Fast Track Status by the U.S. FDA for the Treatment of Systemic Sclerosis August 19, 2015
Corbus Pharmaceuticals Reports 2015 Second Quarter Financial Results and Provides Business Update August 13, 2015
Corbus Pharmaceuticals to Present at the Canaccord Genuity Growth Conference on August 13, 2015 August 6, 2015
Corbus Pharmaceuticals Announces Dosing of First Patient in Phase 2 Clinical Trial of Resunab(TM) for the Treatment of Dermatomyositis July 13, 2015
Corbus Pharmaceuticals to Present at the JMP Securities Life Sciences Conference on June 23, 2015 June 17, 2015
Corbus Pharmaceuticals Announces FDA Orphan Drug Designation for Resunab(TM) for the Treatment of Systemic Sclerosis (Scleroderma) June 12, 2015
Corbus Pharmaceuticals Expands Clinical Development of Resunab(TM) With a Phase 2 Trial for the Treatment of Rare Disease Dermatomyositis June 5, 2015
Corbus Pharmaceuticals Announces Presentation of Positive Data on Resunab(TM) in Pre-Clinical Models of Cystic Fibrosis at the 2015 Cystic Fibrosis Foundation Research Conference June 1, 2015
Corbus Pharmaceuticals Receives FDA Clearance to Initiate Phase 2 Clinical Study of Resunab™ for the Treatment of Cystic Fibrosis May 18, 2015
Corbus Pharmaceuticals Reports 2015 First Quarter Financial Results and Provides Business Update May 13, 2015
Corbus Pharmaceuticals to Present at the Cystic Fibrosis Workshop Hosted by JMP Securities on May 8, 2015 May 4, 2015
Corbus Pharmaceuticals Receives $5 Million Development Award From Cystic Fibrosis Foundation Therapeutics to Advance Resunab™ Clinical Program April 22, 2015
Corbus Pharmaceuticals Announces Presentation of Positive Data on Anti-Fibrotic Effects of Resunab™ in a Preclinical Model of Lung Fibrosis at the Experimental Biology 2015 Scientific Conference April 1, 2015
Corbus Pharmaceuticals' IND Receives Clearance From FDA to Initiate Phase 2 Trials in Scleroderma With Its Novel Specialized Pro-Resolving Mediator Drug Resunab™ March 9, 2015